Jump to content

Search the Community

Showing results for tags 'Docetaxel'.

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • COMMUNITY
    • Announcements, meetings and other resources
  • ADVANCED PROSTATE CANCER FORUMS
    • Primary hormone therapy
    • Secondary hormone therapy
    • Castrate Resistant Prostate Cancer
    • Metastatic
    • Very high risk
    • New agents
    • Every little bit helps
    • Radiation, diagnostic imaging, bones and other prostate cancer topics
    • Articles on other sites
  • MEMBER'S STORIES AND NEEDS
    • My story
    • Any suggestions?
    • The lounge

Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Found 12 results

  1. Kezza2

    Now for Docetaxel

    Well gentlemen, The time has come. I was on abiraterone + apelutimide trial for two years until that failed, and swapped to enzalutimide (Xtandi) but that only lasted three months, and now my PSA has more than doubled from 17 to 38 in 6 weeks, so it seems that docetaxel is next on the list. Having not had docetaxel previously I am not a candidate for the Lu177 trial unfortunately, so I am scheduled to start docetaxel in two weeks. I would appreciate any words of wisdom from the wise who have already been through this on side effects and how to avoid or minimise them, and wh
  2. Jim Marshall (not a doctor) said ... If you have castrate-resistant prostate cancer, common treatments that your doctor may add to your regular ADT treatment include: Docetaxel (Taxotere) Enzalutamide (Xtandi) or Abiraterone (Zytiga) Cabazitaxel (Jevtana). But what are your doctor's drug choices when the cancer is no longer under control after all three options? If you responded to docetaxel, your doctor knows you may well respond again to another dosing of docetaxel. But this increases your risk of side effects - especially peripheral neuropathy or nail di
  3. Jim Marshall (not a doctor) said ... How many doses of the chemotherapy drug Taxotere (Docetaxel) will give longest survival? The number of doses you get depends on how your cancer is responding, and how your body is dealing with it. Six doses of Docetaxel seems to be a common aim (as in the CHARTED trial): But doctors give as many as 10 or more Docetaxel doses in a row (and may repeat that in the future if the first sessions gave a good result). No one has done a study to see if giving more than six doses in a row gives longer survival. But as part of ano
  4. The opportunity There is a chance to have your voice heard on whether the drug Xtandi (enzalutamide) should be available on the PBS BEFORE chemotherapy. Timing Submissions are due Wednesday 8 February 2017, and no late submissions will be accepted. Enzalutamide on the PBS An important drug for men with advanced prostate cancer is Xtandi, also called enzalutamide. The first evidence that enzalutamide worked looked at using enzalutamide AFTER the chemotherapy drug docetaxel. A committee of experts looked at this evidence. They r
  5. Jim Marshall (not a doctor) said ... If you have advanced prostate cancer then chemotherapy with a drug like Taxotere (docetaxel) may be part of your treatment. As your body deals with chemo, there is a risk of serious infection. Back in 2013 we published concise advice from a USA government site about avoiding or dealing with chemotherapy infections. Click on this sentence to read that advice on our site, which also has links to the Prevent Cancer Infections site. ... end Jim
  6. We are all familiar with the concept of intermittent ADT as opposed to continuous ADT. Now researchers are investigating the concept of intermittent chemotherapy as opposed to continuous chemotherapy. If certain criteria are met, there will a break in the chemotherapy treatment and the patient will have a “drug holiday”. In theory intermittent chemotherapy may serve 2 purposes. First, with less constant exposure to the drug, this may potentially delay the development of taxane-refractory disease. Second, breaks in therapy or “drug holidays” ma
  7. Some men may experience a PSA flare when starting docetaxel chemotherapy. The occurrence of PSA flare had no effect on treatment duration or outcome. Joel Nowak at Malecare reports on recent research. Click on this link to read his report. PSA flare is where there is a sharp initial increase in PSA following the commencement of treatment.
  8. Cabazitaxel is a chemotherapy treatment which is used when patients become resistant to chemotherapy treatment with Docetaxel. Cabazitaxel improves overall survival in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with Docetaxel. Androgen receptor splice variant 7 (AR-V7) in circulating tumuor cells (CTCs) from mCRPC patients was recently demonstrated to be associated with resistance to Abiraterone and Enzalutamide. A group of Dutch and Belgian researchers investigated whether this was also true for Cabazitaxel. They found that Cabazitax
  9. The New Prostate Cancer Infolink reports Full data on ADT + chemotherapy from the STAMPEDE trial now published The report has links to the full text of articles in the Lancet regarding this research. "For men with metastatic prostate cancer starting [androgen deprivation] therapy for the first time, we found strong evidence to support the addition of docetaxel to androgen deprivation therapy as the new standard of care, and this combination should be offered to men who are fit to receive chemotherapy. " There is no sufficient evidence yet to recommend docetaxel plus androgen depriva
  10. Dr Charles Myers Jnr (nickname Snuffy Myers) is one of the best known medical oncologists specialising solely on prostate cancer in the USA. He produces a free video on prostate cancer treatment each week, and a paid monthly newsletter service. He also writes books. In a recent video (18 September 2014) Dr Myers talked about Taxotere (brand name Docetaxel) and the CHAARTED trial. Whilst the video deals mainly with early Taxotere use in newly diagnosed patients, there are also some interesting comments about Taxotere use in advanced patients. See this Dr Myers Video at: http:
  11. The U.S. Food and Drug Administration (FDA) has just released a safety warning about the intravenous chemotherapy drug, docetaxel. Docetaxel contains alcohol, which may cause patients to experience intoxication or feel drunk during and after treatment. The FDA suggested that patients should: Avoid driving, operating machinery or doing other activities that are dangerous or require skill one to two hours after you receive treatment with docetaxel. Tell your doctor about all the medicines you are currently taking, as the alcohol in docetaxel may affect other medicines you are usi
  12. Doctors have been starting to use the newer drugs such as Xtandi (enzalutamide) and Zytiga (abiraterone) before docetaxel. This has moved chemotherapy further back in the sequence of treatment. Now there is evidence for a role for earlier chemotherapy for some men. By moving docetaxel from the castration-resistant stage, when men were not responding to testosterone-lowering agents, to the castration-sensitive state, when they were, the survival benefits were amplified. The evidence comes from a clinical trial, “Chemohormonal Therapy versus Androgen Ablation Randomized Trial for Extens
×
×
  • Create New...